Full Press Release Details
INDIANAPOLIS,Dec. 8, 2025/PRNewswire/ -- The board of directors of Eli Lilly and Company (NYSE:LLY) elected Carolyn R. Bertozzi, Ph.D., as a returning member, effective Dec. 8, 2025. She will serve on the board's Science and Technology and Ethics and Compliance committees.
"On behalf of Lilly and the entire board, I would like to welcome Carolyn back to Lilly," said David A. Ricks, Lilly chair and CEO. "Carolyn is a Nobel Prize-winning chemist whose work has fundamentally changed how we think about developing targeted medicines, particularly in cancer. As we continue to pioneer new approaches in oncology and immunology, her perspective will be invaluable. We're fortunate to have her back as we work to deliver more breakthrough medicines to patients."
Currently serving as the Baker Family director of Sarafan ChEM-H, Anne T. and Robert M. Bass professor in the School of Humanities and Sciences and professor, by courtesy, of Chemical and Systems Biology and of Radiology at Stanford University, Dr. Bertozzi is also an Investigator of the Howard Hughes Medical Institute.
She has been recognized with many honors and awards for her research accomplishments and is an elected member of the National Academy of Medicine, National Academy of Sciences and American Academy of Arts and Sciences.
Dr. Bertozzi previously served on Lilly's board from 2017 to 2021.
About LillyLilly is a medicine company turning science into healing to make life better for people around the world. We've been pioneering life-changing discoveries for nearly 150 years, and today our medicines help tens of millions of people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world's most significant health challenges: redefining diabetes care; treating obesity and curtailing its most devastating long-term effects; advancing the fight against Alzheimer's disease; providing solutions to some of the most debilitating immune system disorders; and transforming the most difficult-to-treat cancers into manageable diseases. With each step toward a healthier world, we're motivated by one thing: making life better for millions more people. That includes delivering innovative clinical trials that reflect the diversity of our world and working to ensure our medicines are accessible and affordable. To learn more, visitLilly.comandLilly.com/news, or follow us onFacebook,Instagram, and LinkedIn. C-LLY
Cautionary Statement Regarding Forward-Looking StatementsThis press release contains forward-looking statements (as that term is defined in the Private Securities Litigation Reform Act of 1995) including about research and related initiatives and reflects Lilly's current beliefs and expectations. However, as with any such undertaking, there are substantial risks and uncertainties in the research and development process, manufacturing process, development and commercialization of pharmaceutical products any of which could impact the overall commercial success of our products, and as related to cost, completion timing, expected capacity, personnel, and other factors which could impact expected benefits of the capacity expansion and related initiatives. For further discussion of risks and uncertainties relevant to Lilly's business that could cause actual results to differ from Lilly's expectations, see Lilly's Form 10-K and Form 10-Q filings with the United States Securities and Exchange Commission. Except as required by law, Lilly undertakes no duty to update forward-looking statements to reflect events after the date of this release.
| Refer to: | Carrie Munk;[email protected]; 317-416-2393 (Media) |
| Michael Czapar;[email protected]; 317-617-0983 (Investors) |